Caroline Dive

Last updated
Caroline Dive
CBE
Professor Caroline Dive.jpg
Caroline Dive
BornApril 1962 (age 62)
Alma mater University of London (BPharm)
Scientific career
Fields Cancer
Pharmacology
Institutions Aston University
University of Manchester
Cancer Research UK
Thesis Flow cytoenzymology with special reference to cancer chemotherapy  (1988)
Website www.cruk.manchester.ac.uk/Our-Research/CEP/CEP-Home

Caroline Dive CBE (born April 1962) [1] is a British cancer research scientist. Dive is Professor of Cancer Pharmacology at the University of Manchester, Deputy Director of the Cancer Research UK (CRUK) Manchester Institute, [2] [3] Director of the CRUK Manchester Institute Cancer Biomarker Centre [4] and co-director of the CRUK Lung Cancer Centre of Excellence. [5] She is the current president of The European Association for Cancer Research (EACR). [6]

Contents

Dive's citation upon election as Fellow of the Academy of Medical Sciences describes her as internationally renowned for her work on the development of liquid biopsy methods which use biomarkers circulating in the blood, such as circulating tumour cells and cell-free tumour DNA, to diagnose and monitor cancer. [7]

Education

Dive was educated at the University of London, where she awarded a First Class Honours Bachelor of Pharmacy in 1984. She went on to complete her postgraduate degree in experimental cancer chemotherapy at the MRC Clinical Oncology and Radiotherapeutic Unit in Cambridge.

Research

After completing her PhD, Dive set up her own group at Aston University's School of Pharmaceutical Sciences in Birmingham, studying the mechanisms of drug-induced tumour cell death. She then moved to what became the Faculty of Life Sciences at the University of Manchester and was awarded a Lister Institute of Preventative Medicine Research Fellowship before moving to the Cancer Research UK Manchester Institute in 2003. [8]

It was at the Manchester Institute that she moved away from basic cancer research to set up a new translational research team focussed on biomarkers, working closely with The Christie Hospital in Manchester.

She set up the Clinical Pharmacology Fellowship scheme in 2005 and has been training clinical fellows in the lab ever since. [9]

Dive and her team are developing ‘liquid biopsies’ to hunt cancer cells that have broken free from tumours and are circulating in the bloodstream. Her focus is lung cancer. [10]

Dive says the most important work she's published so far was in 2014, [9] which she said was "a real step change for small cell lung cancer research." They showed that it's possible to take tumour cells that are circulating in a patient's blood and grow them to form tumours in the lab in mice. It was the first time a small cell lung tumour has been grown in this way and didn't require an invasive biopsy. This work allows the team to study lung cancer biology and test new treatments. The work was published in Nature Medicine . [11]

In April 2017, Dive's lab was amongst the Cancer Research UK Manchester Institute labs severely damaged by the fire at the Christie Hospital. [12]

More recently, Dive has been working with Dr Phil Crosbie at the Christie Hospital to deliver Lung Health Checks in supermarket car parks around Manchester, aka 'Scans in Vans'. [13] Smokers and ex-smokers were invited by their GP to attend the check at a mobile van, which would assess their individual lung cancer risk. Those at high risk were offered an immediate CT scan. More than half of those attending qualified for the scan, which identified one cancer for every 33 CT scans. Early detection of lung cancer is key to improving patient outcomes. 9 out of 10 patients diagnosed with a cancer through these scans had the opportunity to have a curative treatment.

She has an h-index of 84 according to Google Scholar. [14]

Awards and honours

Dive was elected as a member of the European Molecular Biology Organization (EMBO) in 2020, [15] [16] a Fellow of the British Pharmacological Society in 2012 [17] [8] and a Fellow of the Academy of Medical Sciences in 2015. [7]

She was appointed Commander of the Order of the British Empire in the 2018 New Year Honours for her services to cancer research. [18]

Dive was awarded the Pasteur-Weizmann/Servier International Prize in 2012 [19] and the AstraZeneca Prize for Women in Pharmacology in 2016. [20] In 2020, she became the first recipient of the Johann Anton Merck Award in honour of her outstanding preclinical research in oncology.

Related Research Articles

<span class="mw-page-title-main">Gordon McVie</span> British oncologist and cancer researcher (1945–2021)

John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

Dame Janet Elizabeth Husband is Emeritus Professor of Radiology at the Institute of Cancer Research. She had a career in diagnostic radiology that spanned nearly 40 years, using scanning technology to diagnose, stage, and follow-up cancer. She continues to support medicine and research as a board member and advisor for various organisations.

<span class="mw-page-title-main">Hani Gabra</span>

Hani Gabra PhD FRCPE FRCP is a British oncologist and Professor Emeritus in Medical Oncology at Imperial College London. Prof Gabra is Founder and Chief Scientific Officer of Papyrus Therapeutics, Inc, a preclinical stage Cancer Biotech company registered in Delaware and currently practises as a Consultant Medical Oncologist at Portsmouth Hospitals NHS Trust, acting as Trust Lead Cancer Clinician.

<span class="mw-page-title-main">Cancer biomarker</span> Substance or process that is indicative of the presence of cancer in the body

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.

<span class="mw-page-title-main">Edinburgh Cancer Research Centre</span> Medical facility in City of Edinburgh, Scotland, UK

The Edinburgh Cancer Research Centre (ECRC), also known as the University of Edinburgh Cancer Research Centre, is a center for basic, translational and clinical cancer research located in Edinburgh, Scotland. ECRC constitutes a part of the Institute of Genetics & Molecular Medicine (IGMM) and is positioned in direct proximity of the Western General Hospital, where most of its clinical activities take place.

A liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is the sampling and analysis of non-solid biological tissue, primarily blood. Like traditional biopsy, this type of technique is mainly used as a diagnostic and monitoring tool for diseases such as cancer, with the added benefit of being largely non-invasive. Liquid biopsies may also be used to validate the efficiency of a cancer treatment drug by taking multiple samples in the span of a few weeks. The technology may also prove beneficial for patients after treatment to monitor relapse.

<span class="mw-page-title-main">Andrea Ablasser</span> German immunologist

Andrea Ablasser is a German immunologist, who works as a full professor of Life Sciences at the École Polytechnique Fédérale de Lausanne. Her research has focused on how the innate immune system is able to recognise virus-infected cells and pathogens.

Sarah-Jane Dawson is an Australian clinician-scientist. She is a consultant medical oncologist and head of the Molecular Biomarkers and Translational Genomics Laboratory at the Peter MacCallum Cancer Centre in Melbourne. Her current research interests are focused on the development of noninvasive blood-based biomarkers for clinical application, including early detection, risk stratification and disease monitoring in cancer management.

<span class="mw-page-title-main">Richard Marais</span> Cancer researcher

Richard Malcolm Marais a British researcher who was Director of the Cancer Research UK (CRUK) Manchester Institute and Professor of Molecular Oncology at the University of Manchester.

<span class="mw-page-title-main">Charles Swanton</span> British physician scientist

Robert Charles Swanton is a British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, Royal Society Napier Professor in Cancer and thoracic medical oncologist at University College London and University College London Hospitals, co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.

Professor James D Brenton is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute and Professor of Ovarian Cancer Medicine in the Department of Oncology, University of Cambridge. He is an Honorary Consultant in Medical Oncology at Addenbrooke's Hospital, Cambridge University Hospitals, Ovarian Cancer Domain Lead for the 100,000 Genomes Project by Genomics England, and co-founder and Clinical Advisor to Inivata Ltd, a clinical cancer genomics company.

Vicky Goh is a professor, chair of clinical cancer imaging, and head of cancer imaging department at the King's College London, England, United Kingdom. She joined King's College London in 2011. She is also a consultant radiologist at Guy's and St Thomas' Hospital in London.

Sally Barrington is a professor of positron emission tomography (PET) Imaging and National Institute for Health Research (NIHR) research professor at King's College London (KCL), England, United Kingdom. She joined KCL in 1993.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

<span class="mw-page-title-main">Sarah Blagden</span> Researcher (ORCID 0000–0001-8783-3491)

Sarah Blagden is a Professor of Experimental Oncology at the University of Oxford. Her laboratory research is in investigating post-transcriptional mechanisms for ovarian cancer behavior. Her clinical research is in conducting early phase trials in novel cancer therapeutics for people with advanced malignancies.

<span class="mw-page-title-main">Alberto Bardelli</span> Italian geneticist

Alberto Bardelli is an Italian geneticist and cancer researcher, expert in the field of precision medicine. He is a full professor of histology at the Department of Oncology, University of Turin and Scientific Director of IFOM, the AIRC Institute of Molecular Oncology.

Sophie Postel-Vinay is a French physician and scientist at the Institut Gustave Roussy where she has led an ATIP-Avenir team since 2018. She works on oncology and the development of new drugs and is an expert in early clinical trials. She was the 2019 winner of the Irène Joliot-Curie Prize in the “young woman scientist” category.

Nitzan Rosenfeld is a professor of Cancer Diagnostics at the University of Cambridge. He is a Senior Group Leader at the Cancer Research UK Cambridge Institute and co-founder of Inivata, a clinical cancer genomics company.

<span class="mw-page-title-main">CNS metastasis</span> Spreading of cancer cells

CNS metastasis is the spread and proliferation of cancer cells from their original tumour to form secondary tumours in portions of the central nervous system.

References

  1. ↑ "Caroline DIVE". Companies House . Retrieved 4 April 2022.
  2. ↑ "Caroline Dive Clinical and Experimental Pharmacology". cruk.manchester.ac.uk.
  3. ↑ Holmes, David (2013). "Caroline Dive: leader in translational oncology research". The Lancet . 381 (9861): 107. doi: 10.1016/S0140-6736(13)60036-7 . ISSN   0140-6736. PMID   23312743. S2CID   19697388.
  4. ↑ "CRUK MI Cancer Biomarker Centre". www.cruk.manchester.ac.uk. Archived from the original on 2019-12-09. Retrieved 2020-07-14.
  5. ↑ "Lung Cancer Centre of Excellence", Cancer Research UK Lung Centre
  6. ↑ "EACR Board | The European Association for Cancer Research". www.eacr.org. Retrieved 2020-07-14.
  7. 1 2 "Fellows directory", The Academy of Medical Sciences
  8. 1 2 "Clinical and Experimental Pharmacology - Professor Caroline Dive", Cancer Research UK Manchester Institute
  9. 1 2 "New Year's Honours 2018: Professor Caroline Dive, CBE, and her career in lung cancer research", Cancer Research UK scienceblog
  10. ↑ "Professor Caroline Dive", Cancer Research UK
  11. ↑ Hodgkinson, Cassandra L.; Morrow, Christopher J.; Li, Yaoyong; Metcalf, Robert L.; Rothwell, Dominic G.; Trapani, Francesca; Polanski, Radoslaw; Burt, Deborah J.; Simpson, Kathryn L.; Morris, Karen; Pepper, Stuart D.; Nonaka, Daisuke; Greystoke, Alastair; Kelly, Paul; Bola, Becky; Krebs, Matthew G.; Antonello, Jenny; Ayub, Mahmood; Faulkner, Suzanne; Priest, Lynsey; Carter, Louise; Tate, Catriona; Miller, Crispin J.; Blackhall, Fiona; Brady, Ged; Dive, Caroline (2014). "Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer". Nature Medicine. 20 (8): 897–903. doi:10.1038/nm.3600. PMID   24880617. S2CID   205393324.
  12. ↑ correspondent, Josh Halliday North of England (2017-04-28). "Manchester cancer hospital fire 'may have destroyed vital research'". The Guardian. ISSN   0261-3077 . Retrieved 2019-03-07.{{cite news}}: |last= has generic name (help)
  13. ↑ "Greater Manchester study revolutionising detection of lung cancer". www.nihr.ac.uk. Retrieved 2019-03-07.
  14. ↑ "Caroline Dive". Google Scholar . Retrieved 4 April 2022.
  15. ↑ "EMBO member profile "Caroline Dive"". Archived from the original on 2020-07-14.
  16. ↑ Warden, Rachel (2020-07-07). "EACR President among newly elected EMBO members". The Cancer Researcher. Retrieved 2020-07-14.
  17. ↑ "Professor Caroline Dive" Archived 2019-03-07 at the Wayback Machine , British Pharmacological Society
  18. ↑ Anon (2017). "Professor Caroline Dive: Order of the British Empire". thegazette.co.uk. The London Gazette.
  19. ↑ "Scientist awarded €150K prize for non-invasive cancer tests", Manchester University
  20. ↑ "Congratulations to our 2016 prize and award winners", British Pharmacological Society
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.